Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Articles|April 1, 2011
- Applied Clinical Trials-04-01-2011
- Volume 20
- Issue 4
Applied Clinical Trials Digital Edition - April 2011
GLOBAL TRIALS : Trials in the Middle East and North Africa Historical Overview: United Kingdom Trials KKS Network Increases Output in Germany Also in this issue : Presidential Panel Considers Tighter Rules, European Union Provides Guidance, Natural Language Processing, Reducing Costs Through Technology
Advertisement
Articles in this issue
over 15 years ago
Business and News Update April 2011over 15 years ago
Demystifying Asian Trialsover 15 years ago
Academic Strength in Germanyover 15 years ago
Imaging CROs in Asiaover 15 years ago
Sponsor Oversight of CROsover 15 years ago
Clinical Research Ethics, Oversight Draws Scrutinyover 15 years ago
Mining for Words: The Case for NLPover 15 years ago
MENA: The Dawn of a New Eraover 15 years ago
Diagnosis on the Run: There's an App for Thatover 15 years ago
Darwin at Work: Trial TechnologyAdvertisement
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
What Needs to Happen Beyond the Clinical Trial Modernization Act
5